Cognito Therapeutics
MA - CambridgeBiotechnology
Focus: Cognito Therapeutics develops device-based brain stimulation therapies focused on neurodegenerative diseases, specifically Alzheimer's disease. The company is a publicly traded biotech with a specialized focus on non-pharmacological neuromodulation approaches.
Profile data last refreshed 20h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
2
Should You Work at Cognito Therapeutics?
AI assessmentCognito represents a high-risk, high-reward early-stage device play suitable for risk-tolerant professionals betting on novel modalities, but limited hiring suggests the company may face resource constraints.
Why Work Here
- Pioneering device-based neurology space with differentiated technology platform positioning you at the forefront of neuromodulation innovation
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
GammaSense Stimulation System
Alzheimer DiseaseClinical Trials (1)
NCT03556280Multi-Center Study of Sensory Stimulation to Improve Brain Function
N/AHelp build intelligence for Cognito Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.